Compare · TRIL vs VIE
TRIL vs VIE
Side-by-side comparison of Trillium Therapeutics Inc. (TRIL) and Viela Bio, Inc. (VIE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TRIL and VIE operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- TRIL carries a market cap of $1.94B.
- TRIL has more recent analyst coverage (5 ratings vs 0 for VIE).
- Company
- Trillium Therapeutics Inc.
- Viela Bio, Inc.
- Price
- $19.30-3.45%
- -
- Market cap
- $1.94B
- -
- 1M return
- -3.79%
- -
- 1Y return
- -5.02%
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2019
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 0
Trillium Therapeutics Inc.
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Latest TRIL
- Defiance ETFs Announces Closure of Select Funds
- Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global Markets
- Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
- 10 Psychedelics CEOs To Pay Attention To In 2022
- Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
- SEC Form 15-12B filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form 4: Walker Paul Edward returned 5,736,363 shares to the company
- SEC Form 4 filed by Pucci Paolo
Latest VIE
- SEC Form 15-12B filed by Viela Bio, Inc.
- SEC Form SC 13D/A filed by Viela Bio, Inc.
- SEC Form 4: Yanling Cao disposed to the issuer $441,084,709 worth of Common Stock (8,322,353 units at $53.00)
- SEC Form 4 filed by Tyrell Rivers
- SEC Form 4 filed by Plc Astrazeneca
- SEC Form 4: Andreas Wicki disposed to the issuer $92,750,000 worth of Common Stock (1,750,000 units at $53.00)
- SEC Form 4: Edward Hu disposed to the issuer $220,542,381 worth of Common Stock (4,161,177 units at $53.00)
- SEC Form 4 filed by Ltd Meadow Boundless
- SEC Form 4: Mitchell Chan disposed to the issuer $1,987,500 worth of Common Stock (37,500 units at $53.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Jorn Drappa disposed to the issuer $10,741,033 worth of Common Stock (202,661 units at $53.00), decreasing direct ownership by 100% to 0 units